Abstract
The Cardiovascular Risk Identification and Treatment Center was established in 1997,
adopting a collaborative-care clinic model for the purpose of improving the management
of high-risk patients with dyslipidemia. This was a retrospective analysis of 417
high-risk patients with ≥1 year of follow-up laboratory data. Analysis included changes
in total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL),
non-HDL, triglycerides, and total cholesterol to HDL ratio; lipoprotein goal achievement;
Framingham risk score; liver function; and cardiovascular events. At baseline, 66%
of patients had coronary heart disease (CHD) or equivalent risk, 45% were not receiving
dyslipidemia therapy, and 29% were on statin monotherapy. After 3 years in the program,
56% were receiving combination therapy, 41% were on monotherapy, and 2% were not on
therapy. The 3 most common treatment regimens were statin plus niacin (36%), statin
alone (22%), and niacin alone (14%). All lipoproteins improved from baseline (p <0.001).
Overall, 62% to 74% of patients reached singular lipid goals and 35% achieved combined
lipid goals. Patients with Framingham 10-year CHD risk of >20% were reduced from 6%
to <1%. Only 29 patients (7.0%) had a cardiovascular event, including 5 (1.0%) who
experienced a myocardial infarction. Aspartate aminotransferase/alanine transferase
elevation >3 times normal occurred in 1% of patients. In conclusion, a collaborative-care
practice model adopting individualized, aggressive pharmacologic and nonpharmacologic
treatment strategies is highly effective in achieving lipid goals, is sustainable,
and is safe. Furthermore, this approach yields reduced projected 10-year CHD risk.
A low rate of cardiovascular events was observed.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nephrology nurse practitioners in a collaborative care model.Am J Kidney Dis. 1998; 31: 786-793
- A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.N Engl J Med. 1995; 333: 1190-1195
- MULTIFIT.Cardiol Clin. 1996; 14: 143-157
- AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular diseasebenefits, rationale, safety, and prescription.Circulation. 2000; 101: 828-833
Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (Adult Treatment Panel III): full report. Bethesda, MD: NIH National Heart, Lung, and Blood Institute. 2001:1–284
- Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.Am J Cardiol. 1999; 83: 1303-1307
- The Lipid Treatment Assessment Project (L-TAP).Arch Intern Med. 2000; 160: 459-467
- EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease.Eur Heart J. 1997; 18: 1569-1582
- Lipid management in a private cardiology practice (the Midwest Heart experience).Am J Cardiol. 2000; 85: 18A-22A
- Reducing low-density lipoprotein cholesterol levels in an ambulatory care system.Arch Intern Med. 1995; 155: 2330-2335
- Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia.Am J Cardiol. 2001; 87: 476-479
- Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.Am J Cardiol. 1995; 76: 182-184
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001; 345: 1583-1592
- Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.N Engl J Med. 1990; 323: 1289-1298
- Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand. 1988; 223: 405-418
- Beneficial effects of colestipol-niacin on coronary atherosclerosis.JAMA. 1990; 264: 3013-3017
- Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA. 1987; 257: 3233-3240
- Angiographic results of lipid-lowering trials.in: Grundy S.M. Cholesterol-Lowering Therapy. Evaluation of Clinical Trial Evidence. Marcel Dekker, Inc, New York2000: 191-220
Article info
Publication history
Accepted:
March 6,
2003
Received in revised form:
March 6,
2003
Received:
December 27,
2002
Identification
Copyright
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
